These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 3596357)
21. Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. The DVTENOX Study Group. Thromb Haemost; 1993 Dec; 70(6):909-14. PubMed ID: 8165610 [TBL] [Abstract][Full Text] [Related]
22. [An open study on the efficacy and tolerance of a low molecular weight heparin (CY 216) in the therapeutic treatment of deep venous thrombi in orthopedics]. Wattrisse G; Lecoutre D; Groux-Pante C; Dufossez F Cah Anesthesiol; 1992; 40(1):37-42. PubMed ID: 1317243 [TBL] [Abstract][Full Text] [Related]
24. Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis. Bratt GA; Törnebohm E; Johanson M; Aberg W; Granqvist S; Lockner D Acta Chir Scand Suppl; 1988; 543():96-100. PubMed ID: 2847465 [TBL] [Abstract][Full Text] [Related]
25. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569 [TBL] [Abstract][Full Text] [Related]
26. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216). Marassi A; Balzano G; Mari G; D'Angelo SV; Della Valle P; Di Carlo V; D'Angelo A Int Surg; 1993; 78(2):166-70. PubMed ID: 8394842 [TBL] [Abstract][Full Text] [Related]
28. [Results of the North Baden Venous Lysis--NBVL--Study. Prospective phlebographically controlled randomized multicenter evaluation of ultra high versus conventional dose streptokinase in acute thrombosis of the leg and pelvic veins]. Heinrich F; Heinrich U Med Klin (Munich); 1996 Jan; 91(1):1-13. PubMed ID: 8839195 [TBL] [Abstract][Full Text] [Related]
29. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Lensing AW; Prins MH; Davidson BL; Hirsh J Arch Intern Med; 1995 Mar; 155(6):601-7. PubMed ID: 7887755 [TBL] [Abstract][Full Text] [Related]
30. Healing of deep venous thrombosis: venographic findings in a randomized study comparing streptokinase and heparin. Rösch J; Dotter CT; Seaman AJ; Porter JM; Common HH AJR Am J Roentgenol; 1976 Oct; 127(4):553-8. PubMed ID: 970521 [TBL] [Abstract][Full Text] [Related]
31. Fibrinolytic and thrombolytic parameters in patients with deep vein thrombosis treated by low molecular weight and standard heparin. Faivre R; Neuhart E; Mirshahi M; Mirshahi M; Soria C; Soria J; Bassand JP; Caen JP; Maurat JP Semin Thromb Hemost; 1989 Oct; 15(4):435-9. PubMed ID: 2554504 [No Abstract] [Full Text] [Related]
32. [Treatment of deep venous thrombosis with low molecular weight heparin (Fragmin)]. Nesvold A; Ly B; Abildgaard U; Stiris M Tidsskr Nor Laegeforen; 1991 Nov; 111(27):3296-7. PubMed ID: 1659751 [TBL] [Abstract][Full Text] [Related]
33. Comparative study on the effects of a low molecular weight heparin (CY 216) and standard heparin in low dosage on experimental venous thrombosis. Doutremepuich C; Bousquet F; Gestreau GL; Toulemonde F; Bayrou B Haemostasis; 1987; 17(4):201-5. PubMed ID: 3623263 [TBL] [Abstract][Full Text] [Related]
34. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis. Breddin HK; Kadziola Z; Scully M; Nakov R; Misselwitz F; Kakkar VV Thromb Haemost; 2003 Feb; 89(2):272-7. PubMed ID: 12574806 [TBL] [Abstract][Full Text] [Related]
35. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Pini M; Aiello S; Manotti C; Pattacini C; Quintavalla R; Poli T; Tagliaferri A; Dettori AG Thromb Haemost; 1994 Aug; 72(2):191-7. PubMed ID: 7831650 [TBL] [Abstract][Full Text] [Related]
36. Liposomal heparin spray: a new formula in adjunctive treatment of superficial venous thrombosis. Górski G; Szopiński P; Michalak J; Marianowska A; Borkowski M; Geremek M; Trochimczuk M; Brotánek J; Sárník S; Seménka J; Wilkowski D; Noszczyk W Angiology; 2005; 56(1):9-17. PubMed ID: 15678251 [TBL] [Abstract][Full Text] [Related]
37. North Baden venous lysis trial (NBVL): multicentre prospective randomized phlebographically controlled trial on the effect of ultra-high versus conventional doses of streptokinase in fresh leg-pelvis venous thromboses. Heinrich F; Heinrich U Vasc Med; 1998; 3(2):87-94. PubMed ID: 9796070 [TBL] [Abstract][Full Text] [Related]
38. [Serious heparin-induced thrombopenia in the treatment of venous thrombosis of the lower limbs]. Millon G; Combe J; Faivre R; Petiteau PY; Bassand JP; Maurat JP; Milleret P Chirurgie; 1983; 109(9):772-7. PubMed ID: 6680685 [No Abstract] [Full Text] [Related]
39. Deep vein thrombosis treated with streptokinase or heparin. Follow-up of a randomized study. Common HH; Seaman AJ; Rösch J; Porter JM; Dotter CT Angiology; 1976 Nov; 27(11):645-54. PubMed ID: 802925 [TBL] [Abstract][Full Text] [Related]
40. [Loco-regional thrombolysis in deep venous thrombosis]. Palombo D; Porta C; Brustia P; Peinetti F; Udini M; Antico A; Maione M; Meloni T; Carbonato P Phlebologie; 1993; 46(2):293-302. PubMed ID: 8362012 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]